Type I interferons in pancreatic cancer and development of new therapeutic approaches

Amber Blaauboer, Kostas Sideras, Casper van Eijck, Leo Hofland

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Web of Science)


Immunotherapy has emerged as a new treatment strategy for cancer. However, its promise in pancreatic cancer has not yet been realized. Understanding the immunosuppressive tumor microenvironment of pancreatic cancer, and identifying new therapeutic targets to increase tumor-specific immune responses, is necessary in order to improve clinical outcomes. Type I interferons, e.g. IFN-α and –β, are considered as an important bridge between the innate and adaptive immune system. Thereby, type I IFNs induce a broad spectrum of anti-tumor effects, including immunologic, vascular, as well as direct anti-tumor effects. While IFN therapies have been around for a while, new insights into exogenous and endogenous activation of the IFN pathway have resulted in new IFN-related cancer treatment strategies. Here, we focus on the pre-clinical and clinical evidence of novel ways to take advantage of the type I IFN pathway, such as IFN based conjugates and activation of the STING and RIG-I pathways.

Original languageEnglish
Article number103204
JournalCritical Reviews in Oncology/Hematology
Publication statusPublished - Mar 2021

Bibliographical note

Publisher Copyright:
© 2020 Elsevier B.V.

Research programs

  • EMC OR-01


Dive into the research topics of 'Type I interferons in pancreatic cancer and development of new therapeutic approaches'. Together they form a unique fingerprint.

Cite this